source
- AGC Biologics targets in-vivo gene therapies with stable producer lines and next-gen purificationThe industry is moving from ex vivo to in vivo gene delivery, a change that forces viral vector manufacturers to rethink scale, purity, cell lines and analytical methods. In in vivo approaches the…
- Arpeggio Biosciences shuts down after Nrf2 drug program encounters off-target toxicityArpeggio Biosciences, founded in 2018 in Boulder, Colorado, built its platform around a large nascent‑RNA sequence database and aimed to develop a small‑molecule degrader of the Nrf2 transcription…